[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-tension-dysphonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-tension-dysphonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,74,101,127,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100527812","voice-therapy-per-the-rehabilitation-treatment-specification-system-100527812",false,"NCT06152627","Voice Therapy Per the Rehabilitation Treatment Specification System","Towards a Unified System to Classify Treatments for Muscle Tension Dysphonia","RTSS-Voice","Inclusion Criteria:\n\n* Diagnosis of primary Muscle Tension Dysphonia (pMTD)\n* Patients with pMTD will be included regardless of subtype (e.g., functional aphonia, vocal fry, ventricular dysphonia) and they can have secondary diagnoses of reflux.\n\nExclusion Criteria:\n\n* Patients diagnosed with pMTD will be excluded if they have secondary diagnoses related to structural, neurological, or respiratory disorders such as laryngitis, obvious vocal fold nodules, polyps, cyst, granuloma, sulci, paradoxical vocal fold motion, chronic cough, confirmed or possible upper airway paralysis\u002Fparesis, dysphagia, polypoid corditis, keratosis, presbylarynx, leukoplakia, or history of radiation to the head\u002Fneck. Patients with pMTD will be included regardless of subtype (e.g., functional aphonia, vocal fry, ventricular dysphonia) and they can have secondary diagnoses of reflux.\n* Non-English speakers. The RTSS-Voice's standard and operationalized categories are in English.","ALL","14 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to evaluate if using evidence-based, standard ingredient and target codes from the Rehabilitation Treatment Specification System - Voice Therapy (RTSS-Voice) in standard of care voice therapy documentation can improve outcomes for patients with muscle tension dysphonia (MTD). The main question it aims to answer is: Since the RTSS-Voice will help clinicians think about their treatment more specifically and in relation to nine evidence-based therapies, will its adoption be associated with improved outcomes? Clinicians across five voice centers will be asked to use the RTSS-Voice to document their voice therapy sessions for patients with MTD. Researchers will compare changes in outcomes between two groups of patients: those treated during the clinician's first year using the RTSS-Voice versus those treated during the clinician's second year using the RTSS-Voice.",[27],"Muscle Tension Dysphonia",[29,30,31],"Muscle tension dysphonia","rehabilitation","treatment","RECRUITING","2026-05-21",{"date":35,"type":36},"2026-05-26","ACTUAL",{"date":38,"type":36},"2026-02-03",{"date":40,"type":21},"2027-06-29",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100289071","imaging-genetics-of-laryngeal-dystonia-100289071","NCT03042975","Imaging Genetics of Laryngeal Dystonia","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background, with age across the lifespan;\n2. Laryngeal Dystonia patients\n\n   * phenotype: adductor or abductor\n   * genotype: familial or sporadic\n3. Voice Tremor patients\n\n   * essential or\n   * dystonic\n4. Muscle tension dysphonia patients\n5. Unaffected relatives of laryngeal dystonia patients with\n\n   * familial laryngeal dystonia\n   * early-onset laryngeal dystonia (onset at ≤ 35 y.o.)\n   * typical onset laryngeal dystonia (onset at ≥ 40 y.o.)\n6. Native English speakers.\n7. Right-handedness.\n8. Normal cognitive status.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent.\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding.\n3. Subjects with past or present medical history of (a) major neurological problems, such as stroke, movement disorders (other than LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder; (c) laryn¬geal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.\n4. Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles.\n5. Subjects who receive medication(s) affecting the central nervous system.\n6. Subjects with a history of major brain and\u002For laryngeal surgery.\n7. Subjects who have tattoos, ferromagnetic objects in their bodies that cannot be removed for imaging study participation.",{"count":52,"type":21},410,"OBSERVATIONAL","The contribution of genetic risk factors to the development of focal dystonias is evident. However, understanding of how variations in the causative gene expression lead to variations in brain abnormalities in different phenotypes of dystonia (e.g., familial, sporadic) remains limited. The research program of the investigators is set to determine the relationship between brain changes and genetic risk factors in laryngeal dystonia (or spasmodic dysphonia). The researchers use a novel approach of combined imaging genetics, next-generation DNA sequencing, and clinical-behavioral testing. The use of a cross-disciplinary approach as a tool for the discovery of the mediating neural mechanisms that bridge the gap from DNA sequence to the pathophysiology of dystonia holds a promise for the understanding of the mechanistic aspects of brain function affected by risk gene variants, which can be used reliably for the discovery of associated genes and neural integrity markers for this disorder. The expected outcome of this study may lead to better clinical management of this disorder, including its improved detection, accurate diagnosis, and assessment of the risk of developing dystonia in family members.",[56,57,58,27],"Laryngeal Dystonia","Unaffected Relatives of Laryngeal Dystonia Patients","Voice Tremor",[60,61,62,63],"dystonia","spasmodic dysphonia","imaging","genetics","2025-11-24",{"date":66,"type":36},"2025-12-02",{"date":68,"type":36},"2017-01-23",{"date":70,"type":21},"2028-07-31",{"name":72,"class":43},"Kristina Simonyan",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":73},"100604097","phase-3-translaryngeal-vibration-for-hyperfunctional-voice-disorders-100604097","NCT07145086","Translaryngeal Vibration for Hyperfunctional Voice Disorders","Inclusion Criteria:\n\n* a) diagnosis by an otolaryngologist of hyperfunctional dysphonia (MTD) without benign mid-membranous lesion (i.e., primary MTD or non-phonotraumatic hyperfunction) with and a recommendation for voice therapy, ((b) confirmation of dysphonia by a comprehensive voice evaluation conducted by a speech-language pathologist with experience in the evaluation and treatment of voice disordered populations, (c) to prevent floor effects of our primary outcome variable, participants will be required to exhibit a pre-treatment VHI score of \\>20, as this is the upper range for normal cutoff values in studies which have demonstrated high sensitivity and specificity for this tool (Behlau et al., 2016), (d) 18 years of age or older, (e) no history of local vibration therapy as part of a rehabilitation treatment program.\n\nExclusion Criteria:\n\n* Unable to receive vibration to neck area",true,"18 Years",{"count":83,"type":21},30,[85],"PHASE3","Contemporary treatments for hyperfunctional voice disorders such as muscle tension dysphonia (MTD) are effective but typically do not restore voice handicap or voice function to normal thresholds. Recent reports of vibration as a voice therapy modality have been published, but many questions remain about the efficacy of this tool. The current project addresses these problems through a blinded and randomized controlled trial to investigate the efficacy of local translaryngeal vibration for MTD and the dose-response relationship of this modality when compared to treatment without vibration.",[88,27],"Dysphonia",[88,27,90,91],"Voice Therapy","Vibration","2025-08-20",{"date":94,"type":36},"2025-08-28",{"date":96,"type":36},"2024-09-01",{"date":98,"type":21},"2027-08-31",{"name":100,"class":43},"Texas Christian University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100513829","early-phase-1-project-4-ambulatory-biofeedback-and-voice-therapy-for-patients-with-vocal-hyperfunction-100513829","NCT05970562","Project 4: Ambulatory Biofeedback and Voice Therapy for Patients With Vocal Hyperfunction","Preliminary Studies to Test the Effects of Ambulatory Biofeedback in Small Groups of Patients With Vocal Hyperfunction: Study 3","Inclusion criteria for PVH:\n\n* Diagnosis of vocal fold nodules and polyps.\n* Secondary diagnosis of laryngopharyngeal reflux (LPR) or gastro-esophageal reflux disease (GERD)\n* Secondary diagnoses commonly associated with phonotrauma like erythema, edema, varies, ectasia, laryngitis, secondary\u002Freactive muscle tension dysphonia (MTD), hemorrhage, etc.\n\nExclusion criteria for PVH:\n\n* Any secondary diagnosis not directly related to phonotrauma, like cyst, sulk, cancer, bamboo nodule, known or suspected paralysis, etc.\n\nInclusion criteria for NPVH:\n\n* Diagnosis of primary MTD.\n* Allowable secondary diagnoses are LPR and GERD.\n\nExclusion criteria for NPVH:\n\n* Any secondary diagnosis related to pathological structure (e.g., nodules, polyps, edema, cancer), neurology (e.g., paralysis, Parkinson's Disease), or respiration (e.g., chronic cough, paradoxical vocal fold motion).","65 Years",{"count":110,"type":21},100,[112],"EARLY_PHASE1","Vocal hyperfunction (VH) is the most commonly treated class of voice disorders by speech-language pathologists and voice therapy is the primary curative treatment. Patients and clinicians report that generalizing improved voicing into daily life is the most significant barrier to successful therapy. We will test if extending biofeedback into the patient's daily life using ambulatory voice monitoring will significantly improve generalization during therapy and if individual patient factors, like how easily they can modify their voice and engagement during therapy, moderate the effects of the biofeedback.",[115,116,117,27],"Voice Disorders","Vocal Fold Polyp","Vocal Nodules in Adults","2025-05-07",{"date":120,"type":36},"2025-05-11",{"date":122,"type":36},"2024-03-01",{"date":124,"type":21},"2029-04-01",{"name":42,"class":43},2,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":73},"100556368","rct-face-to-face-group-voice-therapy-vs-telepractice-group-voice-therapy-for-muscle-tension-dysphonia-100556368","NCT06524193","RCT Face-to-face Group Voice Therapy vs Telepractice Group Voice Therapy for Muscle Tension Dysphonia","Comparing Face-to-face Group Voice Therapy to Telepractice Group Voice Therapy for Muscle Tension Dysphonia: A Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* Above or equal to 18 years of age;\n* Diagnosis of primary MTD or secondary MTD where voice therapy is the primary mode of treatment, such as vocal fold nodules;\n* Chinese-speaking subjects only.\n\nExclusion Criteria:\n\n* Dysphonia of neurogenic or psychogenic origin;\n* Secondary muscle tension dysphonia in which voice therapy is not the primary treatment modality, such as vocal polyp, vocal cyst, granuloma, papilloma;\n* Low computer literacy or without social or family support for telepractice;\n* Patients who are not capable of making own consent;\n* Patients who are receiving other modalities of treatment which is not part of this current study, such as traditional Chinese medicine.",{"count":135,"type":21},168,[24],"The goal of this clinical trial is to compare face-to-face group voice therapy to telepractice group voice therapy for muscle tension dysphonia (MTD). The main questions it aims to answer are:\n\n* The effectiveness of telepractice voice therapy for MTD using a randomized controlled trial study design.\n* The effectiveness of telepractice group voice therapy using a randomized controlled trial study design.\n\nParticipants will receive telepractice group voice therapy or face-to-face group voice therapy. Researchers will compare telepractice group voice therapy to face-to-face group voice therapy for patients with MTD to see if it has the same effectiveness.",[115,27,139],"Aphonia",[115,27,141,142,143,90,144],"Group Therapy","Telepractice","Service Delivery Model of Voice Therapy","Randomised controlled trail","2024-07-26",{"date":147,"type":36},"2024-07-29",{"date":149,"type":36},"2024-06-25",{"date":151,"type":21},"2026-07",{"name":153,"class":43},"Chinese University of Hong Kong",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":73},"100523814","autonomic-dysfunction-in-functional-dysphonia-100523814","NCT06100601","Autonomic Dysfunction in Functional Dysphonia","Patients with functional dysphonia will be recruited from a treatment-seeking population consulting at the voice clinic of Ghent University Hospital. Inclusion criteria are all genders, all ethnicities, aged 18 - 60 years (to exclude voice-related changes due to puberty\u002Fmutation or aging\u002Fpresbyphonia), diagnosed with FD by an experienced otorhinolaryngologist and SLP (defined by a voice disorder in the absence of organic or structural mucosal disease and\u002For neuropathology sufficient to explain the voice disturbance (Roy et al., 2003), as determined with strobovideolaryngoscopy and a multidimensional voice assessment). Exclusion criteria include: being diagnosed with an organic voice disorder, current participation in voice therapy, practice of breathing exercises including mediation and yoga, current participation in psychotherapy or physical rehabilitation, pharmacological treatment (i.e. antidepressants, antipsychotics, heart medication, antihypertensives, inhalers), previous phonosurgical interventions, lung diseases, endocrinologic diseases, metabolic diseases, cardiovascular diseases, neurologic diseases, nasal or ear diseases, pregnancy, asthma, smoking or drug consumption.\n\nFor the vocally healthy controls, inclusion criteria are all genders, all ethnicities, aged 18 - 60 years, and matched with the FD groups by age and gender. The same exclusion criteria as above apply, with the addition of: 'diagnosed with FD'.","60 Years",{"count":110,"type":21},[24],"The first objective of this research project is to compare the occurrence and frequency of symptoms and\u002For disorders related to autonomic dysfunction in patients with functional dysphonia with gender- and age-matched vocally healthy controls, using a case-control study.\n\nThe second objective is to compare the effects of a novel therapy based on autonomic nervous system regulation (i.e., ANS therapy: heart rate variability biofeedback), for functional dysphonia versus coventional voice therapy (CVT) alone or in combination with ANS regulation therapy (i.e., ANS therapy + CVT), using a longitudinal randomized controlled trial (RCT).",[165,166,27],"Functional Voice Disorder","Psychogenic Voice Disorder",[168],"Autonomic nervous system, functional dysphonia, heart rate variability, psychophysiology","2023-10-20",{"date":171,"type":36},"2023-10-25",{"date":173,"type":36},"2023-10-10",{"date":175,"type":21},"2026-12",{"name":177,"class":43},"University Ghent"]